Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| No statute on record | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BASQUILL, SEAN M | 1 | 38.6% | +22.5% |
| ENGLISH, CONNOR KENNEDY | 1 | 55.9% | +55.6% |
| ISMAIL, REHANA | 1 | 78.9% | +30.2% |
| SAMSELL, RILLA MARIE | 1 | 71.4% | +0.0% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 56.8% | +41.6% |
| NESTOR, DONNA MICHELLE | 1 | 57.5% | +43.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549778 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | ENGLISH, CONNOR KENNEDY | 25d overdue |
| 17769416 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | NESTOR, DONNA MICHELLE | 25d overdue |
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 5d overdue |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | ISMAIL, REHANA | 7d |
| 18006603 | COMBINATION THERAPY OF PARP INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 42d |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1627 | 2 |
| 1614 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 1614 | §103 | Non-Final OA | 5d overdue | Pending | Sep 25, 2023 |
| 18549778 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | ENGLISH, CONNOR KENNEDY | 1625 | Other | Non-Final OA | 25d overdue | Pending | Sep 08, 2023 |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | ISMAIL, REHANA | 1625 | Other | Non-Final OA | 7d | Pending | Jun 23, 2023 |
| 18255476 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | SAMSELL, RILLA MARIE | 1624 | Other | Non-Final OA | 22d overdue | Pending | Jun 01, 2023 |
| 18006603 | COMBINATION THERAPY OF PARP INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Non-Final OA | 42d | Pending | Jan 24, 2023 |
| 17769416 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | NESTOR, DONNA MICHELLE | 1627 | Other | Final Rejection | 25d overdue | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial